Laura Pizzuti Selected Research

Neoplasm Metastasis (Metastasis)

1/2022	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
4/2020	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
1/2019	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
1/2019	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
9/2017	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.
8/2017	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.
3/2014	Immunologic treatments for precancerous lesions and uterine cervical cancer.
5/2013	Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Pizzuti Research Topics

Disease

59	Breast Neoplasms (Breast Cancer) 05/2024 - 07/2006
47	Neoplasms (Cancer) 01/2023 - 01/2012
9	Triple Negative Breast Neoplasms 01/2023 - 12/2015
8	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2013
7	Male Breast Neoplasms (Male Breast Cancer) 10/2016 - 08/2013
5	Disease Progression 05/2024 - 08/2013
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2021 - 01/2014
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2020 - 01/2012
4	Stomach Neoplasms (Stomach Cancer) 01/2018 - 09/2013
3	Cardiotoxicity 01/2023 - 01/2014
2	Pathologic Complete Response 01/2023 - 09/2020
2	Adenocarcinoma of Lung 12/2021 - 11/2019
2	Obesity 11/2020 - 10/2016
2	Brain Neoplasms (Brain Tumor) 04/2020 - 01/2019
2	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2019 - 01/2019
2	Ovarian Neoplasms (Ovarian Cancer) 02/2018 - 08/2013
2	Rare Diseases (Rare Disease) 08/2017 - 11/2014
2	Ovarian Epithelial Carcinoma 01/2016 - 08/2013
1	Vulvar Neoplasms (Vulvar Cancer) 08/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2020
1	Colonic Neoplasms (Colon Cancer) 04/2020
1	Melanoma (Melanoma, Malignant) 04/2020
1	Carcinoma (Carcinomatosis) 04/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 04/2020
1	Squamous Cell Carcinoma of Head and Neck 04/2020
1	COVID-19 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Ataxia (Dyssynergia) 01/2019
1	Anaplasia 01/2019
1	Genomic Instability 01/2018

Drug/Important Bio-Agent (IBA)

15	Hormones (Hormone)IBA 01/2023 - 08/2013
14	Trastuzumab (Herceptin)FDA Link 01/2023 - 05/2013
11	Biomarkers (Surrogate Marker)IBA 11/2022 - 10/2014
9	AnthracyclinesIBA 01/2022 - 04/2011
9	Immune Checkpoint InhibitorsIBA 12/2021 - 11/2017
8	Taxoids (Taxanes)IBA 01/2023 - 05/2013
8	Phenobarbital (Luminal)FDA Link 11/2021 - 10/2014
7	human ERBB2 proteinIBA 11/2023 - 10/2014
7	pertuzumabIBA 01/2023 - 01/2017
5	eribulin FDA Link 01/2021 - 01/2014
5	Phosphotransferases (Kinase)IBA 11/2019 - 01/2012
5	Estrogen ReceptorsIBA 09/2019 - 10/2014
5	Glucose (Dextrose)FDA LinkGeneric 02/2018 - 11/2014
4	Capecitabine (Xeloda)FDA Link 01/2023 - 05/2013
4	Cyclin-Dependent Kinase 4IBA 01/2023 - 12/2020
4	Fulvestrant (Faslodex)FDA Link 11/2021 - 08/2017
4	exemestane (Aromasin)FDA Link 12/2020 - 01/2017
4	Everolimus FDA Link 12/2020 - 01/2017
4	Progesterone Receptors (Progesterone Receptor)IBA 04/2017 - 07/2006
4	Gonadotropin-Releasing Hormone (GnRH)FDA Link 05/2015 - 08/2013
3	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2019
3	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 12/2015
3	Estrogens (Estrogen)FDA Link 01/2021 - 07/2006
3	palbociclibIBA 01/2021 - 01/2019
3	Ado-Trastuzumab EmtansineIBA 01/2021 - 01/2017
3	PlatinumIBA 04/2020 - 08/2013
3	Androgen Antagonists (Antiandrogens)IBA 11/2015 - 11/2014
3	Aromatase InhibitorsIBA 05/2015 - 08/2013
2	ribociclibIBA 01/2022 - 01/2021
2	Indicators and Reagents (Reagents)IBA 11/2020 - 01/2016
2	NivolumabIBA 04/2020 - 01/2019
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 02/2015
2	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 06/2017
2	Bevacizumab (Avastin)FDA Link 01/2018 - 06/2017
2	Oncogene Proteins (Oncogene Protein)IBA 06/2016 - 01/2016
2	Androgen Receptors (Androgen Receptor)IBA 11/2015 - 11/2014
2	Cyproterone AcetateIBA 05/2015 - 11/2014
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2014 - 08/2013
2	Docetaxel (Taxotere)FDA Link 10/2014 - 09/2013
2	liposomal doxorubicin (Doxil)FDA Link 01/2014 - 04/2011
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 07/2007 - 07/2006
1	CyclinsIBA 01/2023
1	MicroRNAs (MicroRNA)IBA 11/2022
1	Interferon Type IIBA 01/2022
1	GenieIBA 12/2021
1	abemaciclibIBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	Epidermal Growth Factor (EGF)IBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 09/2020
1	atezolizumabIBA 09/2020
1	LigandsIBA 09/2020
1	B7-H1 AntigenIBA 04/2020
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2019
1	taxaneIBA 01/2019
1	Histones (Histone)IBA 01/2019
1	Tamoxifen FDA LinkGeneric 01/2019
1	AutoantibodiesIBA 01/2019
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 02/2018
1	antithrombin III-protease complexIBA 01/2018

Therapy/Procedure

33	Therapeutics 05/2024 - 08/2013
19	Drug Therapy (Chemotherapy) 01/2022 - 07/2013
15	Neoadjuvant Therapy 01/2023 - 01/2014
4	Immunotherapy 12/2021 - 03/2014
2	Combination Drug Therapy (Combination Chemotherapy) 03/2015 - 10/2014
1	Modified Radical Mastectomy (Mastectomy, Modified) 01/2023
1	Radiotherapy 01/2021
1	Drug Tapering 01/2021
1	Contraindications 01/2019
1	Metronomic Administration 01/2019